. Author manuscript; available in PMC: 2021 May 26.

Published in final edited form as: Inorganics (Basel). 2020 Jan 26;8(2):10. doi: 10.3390/inorganics8020010

Table 2.

Antiproliferative activities (μM ± SD) of Ti(IV)–Au(I) complexes against cancer cell lines.

Compounds	A498 Kidney	UO31 Kidney	Caki-1 Kidney	HEK-293T Kidney	PC3 Prostate	DU145 Prostate
Cp₂Ti-(OC(O)-4-C₆H₄PPh₂AuCl)₂	6.9 ± 2.2	0.3 ± 0.06	1.0 ± 0.29	20.1 ± 1.6	37.7 ± 7.1	6.6 ± 1.8
HOC(O)-4-C₆H₄PPh₂AuCl	21 ± 2.5	1.2 ± 0.8	19.2 ± 2.9	31 ± 0.9	78 ± 18.1	39 ± 5.7
Cp₂Ti-OC(O)-4-C₆H₄SAuPPh₃	ND	ND	0.12 ± 0.003	0.49 ± 0.008	ND	ND
C₆H₄SAuPPh₃	ND	ND	2.76 ± 0.35	1.11 ± 0.65	ND	ND
Cisplatin	37.2 ± 4.6	8.9 ± 2.7	29 ± 4.1	3.2 ± 0.13	14 ± 2.3	12.1 ± 3.9
Cp₂TiCl₂	>200	>200	>200	>200	>200	>200
Titanocene Y	29.6 ± 2.8	>200	29.4 ± 4.2	>200	58.1 ± 11.2	55.2 ± 7.9